NewAmsterdam Pharma (NAMS) Stock Forecast & Price Target

$20.00 -0.02 (-0.10%)

(As of 11/21/2024 ET)

NewAmsterdam Pharma - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 6 Analyst Ratings

Sell
0

Hold
0

Buy
6

Based on 6 Wall Street analysts who have issued ratings for NewAmsterdam Pharma in the last 12 months, the stock has a consensus rating of "Buy." Out of the 6 analysts, 6 have given a buy rating for NAMS.

Consensus Price Target

$33.80
69.04% Upside

According to the 6 analysts' twelve-month price targets for NewAmsterdam Pharma, the average price target is $33.80. The highest price target for NAMS is $37.00, while the lowest price target for NAMS is $30.00. The average price target represents a forecasted upside of 69.04% from the current price of $20.00.

Get the Latest News and Ratings for NAMS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for NewAmsterdam Pharma and its competitors.

NAMS Analyst Ratings Over Time

Type	Current Forecast 11/23/23 to 11/22/24	1 Month Ago 10/24/23 to 10/23/24	3 Months Ago 8/25/23 to 8/24/24	1 Year Ago 11/23/22 to 11/23/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$33.80	$33.80	$33.25	$22.50
Forecasted Upside	69.04% Upside	75.13% Upside	104.49% Upside	127.50% Upside
Consensus Rating	Buy	Buy	Buy	Buy

Can Trump Make Housing Great Again? (Ad)

Trump won. But can he undo the damage the Democrats have inflicted on this nation? Under Biden, inflation soared 20%... Which could be the final blow for the American Dream - even with Trump in office.

Take these three steps today to protect your retirement from Biden's legacy >>>

NAMS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NAMS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

NewAmsterdam Pharma Stock vs. The Competition

Type	NewAmsterdam Pharma	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	69.04% Upside	26,677.72% Upside	8.51% Upside
News Sentiment Rating	Neutral News See Recent NAMS News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/21/2024	Needham & Company LLC 3 of 5 stars	S. Belanger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00	+79.91%
9/23/2024	Piper Sandler 2 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$37.00 ➝ $37.00	+132.41%
9/5/2024	Royal Bank of Canada 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$31.00 ➝ $31.00	+90.07%
5/15/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy
3/14/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Sector Outperform ➝ Sector Outperform	$35.00	+56.95%
1/18/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$30.00	+79.10%
11/22/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
4/3/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$21.00 ➝ $22.00	+65.91%
12/20/2022	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Ruiz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$19.00	+67.99%
12/19/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$24.00	+123.88%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:42 AM ET.

NAMS Forecast - Frequently Asked Questions

: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for NewAmsterdam Pharma is $33.80, with a high forecast of $37.00 and a low forecast of $30.00.
: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NewAmsterdam Pharma in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NAMS shares.
: According to analysts, NewAmsterdam Pharma's stock has a predicted upside of 69.04% based on their 12-month stock forecasts.
: NewAmsterdam Pharma has been rated by research analysts at Needham & Company LLC, Piper Sandler, and Royal Bank of Canada in the past 90 days.
: Analysts like NewAmsterdam Pharma more than other "medical" companies. The consensus rating for NewAmsterdam Pharma is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NAMS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

What do “they” know that you don’t? (Ad)

Over the past decade, the Central Bank trade has been clear: Sell Treasuries, buy gold. In fact, Central Banks have now DOUBLED their gold stake - sending stockpiles to the highest level since the '90s, according to The Kobeissi Letter.

No. 1 way to profit from gold's rise, and you can get started for less than $10.

This page (NASDAQ:NAMS) was last updated on 11/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NewAmsterdam Pharma (NAMS) Stock Forecast & Price Target